• The industry-sponsored, international, multicenter, randomized, double-blind, active-
comparator trial, PARADISE-MI 1 (Prospective ARNI vs. ACE Inhibitor Trial to Determine …

Although angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers
(ARBs), and β-blockers have been proved to reduce mortality in patients with heart failure …

269 Current Phramacological Targets of Systolic HF tors have had proven benefit in LV
dysfunction following myocardial infarction (MI). In the SAVE trial, captopril was …

Despite the widespread use of early revascularization and drugs to regulate the
neuroendocrine system, the impact of such measures on alleviating the development of …

Chronic heart failure is a complex syndrome involving the activation of multiple cellular,
metabolic and neurohumoral pathways following the initial myocardial insult. Because of the …

Background Left ventricular dysfunction after an acute myocardial infarction (MI) is
associated with poor outcome. The PARADISE-MI trial is examining whether an angiotensin …

Aims We analysed the contemporary incidence, outcomes, and predictors of heart failure
(HF) and/or left ventricular systolic dysfunction (LVSD) before discharge in patients with …

Heart failure is a frequent complication of myocardial infarction. Several factors, such as
recurrent myocardial ischemia, infarct size, ventricular remodeling, stunned myocardium …

Heart failure (HF) complicating myocardial infarction (MI) is common and may be present at
admission or develop during the hospitalization. Among patients with MI, there is a strong …

Introduction: This was a propensity score analysis of the prospective, randomized, double-
blind Survival of Myocardial Infarction Long-term Evaluation (SMILE) 4 study in which one …